Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease

Expert Opinion on Biological Therapy

Volumn 3, Issue 3, 2003, Pages 477-486

  Chu, N Randall ^a  

^a StressGen Biotechnologies Corp   (Canada)

Author keywords

Fusion proteins; Genital warts; Heat shock proteins; Hsp65; Human papillomavirus; Immunity; Immunotherapeutic; Papillomavirus; Vaccine

Indexed keywords

ADJUVANT; COVAL; CYTOTOXIC AGENT; HEAT SHOCK PROTEIN; HEPATITIS B CORE ANTIGEN; HPV16 E7 VACCINE; HUMAN PAPILLOMA VIRUS ANTIGEN; HYBRID PROTEIN; IMIQUIMOD; NUCLEOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN; WART VIRUS VACCINE;

CHIMERA; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; FUSION GENE; GENE DELIVERY SYSTEM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; PAPILLOMA VIRUS; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE;

ANIMALS; HUMANS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VACCINATION; VIRAL VACCINES;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS;

EID: 0037526586     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.3.477     Document Type: Review

References (107)

1. ZUR HAUSEN H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. (2000) 92:690-698.
2. ZUR HAUSEN H: Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta. (1996) 1288:F55-F78.
3. KJAER SK, VAN DEN BRULE AJ, BOCK JE et al.: Human papillomavirus-the most significant risk determinant of cervical intraepithelial neoplasia. Int. J. Cancer (1996) 65:601-606.
4. BOSCH FX, MANOS MM, MUNOZ N et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl. Cancer Inst. (1995) 87:796-802.
5. BOSCH FX, LORINCZ A, MUNOZ N, MEIJER CJ, SHAH KV: The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. (2002) 55:244-265. A definitive argument for citing high-risk HPV as a necessary cause of cervical cancer.
6. FRISCH M, GLIMELIUS B, VAN DEN BRULE AJ et al.: Sexually transmitted infection as a cause of anal cancer. N. Engl. J. Med. (1997) 337:1350-1358.
7. SUGASE M, MATSUKURA T: Distinct manifestations of human papillomaviruses in the vagina. Int. J. Cancer (1997) 72:412-415.
8. VAN HOUTEN VM, SNIJDERS PJ, VAN DEN BREKEL MW et al.: Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int. J. Cancer (2001) 93:232-235.
9. BROWN DR, SCHROEDER JM, BRYAN JT, STOLER MH, FIFE KH: Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J. Clin. Microbiol. (1999) 37:3316-3322.
10. GISSMANN L, WOLNIK L, IKENBERG H, KOLDOVSKY U, SCHNURCH HG, ZUR HAUSEN H: Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA (1983) 80:560-563.
11. AUBORN KJ: Therapy for recurrent respiratory papillomatosis. Antiviral Ther. (2002) 7:1-9.
12. KOUTSKY L: Epidemiology of genital human papillomavirus infection. Am. J. Med. (1997) 102:3-8.
13. HO GY, BIERMAN R, BEARDSLEY L, CHANG CJ, BURK RD: Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. (1998) 338:423-428.
14. HO GY, BURK RD, KLEIN S et al.: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. (1995) 87:1365-1371.
15. SYRJANEN KJ: Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur. J. Obstet. Gynecol. Reprod. Biol. (1996) 65:45-53.
16. PALEFSKY JM, HOLLY EA, RALSTON ML et al.: Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) 17:320-326.
17. CARRASCO D, STRATEN MV, TYRING SK: Prophylactic and therapeutic vaccines for genital papillomavirus infection. J. Investig. Dermatol. Symp. Proc. (2001) 6:238-243.
18. DA SILVA DM, EIBEN GL, FAUSCH SC et al.: Cervical cancer vaccines: emerging concepts and developments. J. Cell Physiol. (2001) 186:169-182. Thorough review of the HPV vaccine field.
19. GISSMANN L, OSEN W, MULLER M, JOCHMUS I: Therapeutic vaccines for human papillomaviruses. Intervirology (2001) 44:167-175.
20. STERN PL, FAULKNER R, VERANES EC, DAVIDSON EJ: The role of human papillomavirus vaccines in cervical neoplasia. Best Pract. Res. Clin. Obstet. Gynaecol. (2001) 15:783-799.
21. KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347:1645-1651.
22. SOUTTER WP, DE BARROS LOPES A, FLETCHER A et al.: Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 349:978-980.
23. BALDAUF JJ, DREYFUS M, RITTER J, CUENIN C, TISSIER I, MEYER P: Cytology and colposcopy after loop electrosurgical excision: implications for follow-up. Obstet. Gynecol. (1998) 92:124-130.
24. SCHOLEFIELD JH, OGUNBIYI OA, SMITH JH, ROGERS K, SHARP F: Treatment of anal intraepithelial neoplasia. Br. J. Surg. (1994) 81:1238-1240.
25. SONNEX C, LACEY CJ: The treatment of human papillomavirus lesions of the lower genital tract Best Pract. Res. Clin. Obstet. Gynaecol. (2001) 15:801-816.
26. TYRING SK: Immune-response modifiers: a new paradigm in the treatment of Human Papillomavirus. Curr. Ther. Res. Clin. Exp. (2000) 61:584-596.
27. FIFE KH, FERENCZY A, DOUGLAS JM JR, BROWN DR, SMITH M, OWENS ML: Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex. Transm. Dis. (2001) 28:226-231.
28. BEUTNER KR, FERENCZY A: Therapeutic approaches to genital warts. Am. J. Med. (1997) 102:28-37.
29. HERRINGTON CS: Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors. J. Clin. Pathol. (1995) 48:1-6.
30. MCLACHLIN CM: Pathology of human papillomavirus in the female genital tract. Curr. Opin. Obstet. Gynecol. (1995) 7:24-29.
31. COLEMAN N, BIRLEY HD, RENTON AM et al.: Immunological events in regressing genital warts. Am. J. Clin. Pathol. (1994) 102:768-774.
32. NICHOLLS PK, MOORE PF, ANDERSON DM et al.: Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology (2001) 283:31-39.
33. BREITBURD F, SALMON J, ORTH G: The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Clin. Dermatol. (1997) 15:237-247.
34. ALANI RM, MUNGER K: Human papillomaviruses and associated malignancies. J. Clin. Oncol. (1998) 16:330-337.
35. CHEN LP, THOMAS EK, HU SL, HELLSTROM I, HELLSTROM KE: Human papillomavirus Type 16 nudeoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA (1991) 88:110-114.
36. FELTKAMP MC, SMITS HL, VIERBOOM MP et al.: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus Type 16-transformed cells. Eur. J. Immunol. (1993) 23:2242-2249. Key paper describing the use of an E7 peptide epitope as an immunoprophylactic agent.
37. LIN KY, GUARNIERI FG, STAVELEY-O'CARROLL KF et al.: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. (1996) 56:21-26. Key paper demonstrating the utility of an E7 fusion construct as an immunotherapeutic agent.
38. ZEHBE I, WILANDER E, DELIUS H, TOMMASINO M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. (1998) 58:829-833.
39. NINDL I, RINDFLEISCH K, LOTZ B, SCHNEIDER A, DURST M: Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int. J. Cancer (1999) 82:203-207.
40. DE JONG A, VAN DER BURG SH, KWAPPENBERG KM et al.: Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. (2002) 62:472-479.
41. VAN DER BURG SH, DE JONG A, WELTERS MJ, OFFRINGA R, MELIEF CJ: The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res. (2002) 89:275-284. Concise review on issues facing HPV therapeutic vaccine field.
42. FRAZER IH, THOMAS R, ZHOU J et al.: Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev. (1999) 168:131-142. Detailed explanation of HPV immune evasion strategies.
43. TINDLE RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer (2002) 2:59-65. See [42].
44. PARDOLL DM: Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. (2002) 2:227-238. Clear 'roadmap' for the variety of available immunotherapeutic strategies.
45. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252.
46. HEATH WR, CARBONE FR: Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. (1999) 11:314-318.
47. SCHIJNS VE: Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. (2000) 12:456-463.
48. LEACHMAN SA, SHYLANKEVICH M, SLADE MD et al.: Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. Virol. (2002) 76:7616-7624.
49. KAST WM, BRANDT RM, SIDNEY J et al.: Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus Type 16 E6 and E7 proteins. J. Immunol. (1994) 152:3904-3912.
50. RESSING ME, SETTE A, BRANDT RM et al.: Human CTL epitopes encoded by human papillomavirus Type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. (1995) 154:5934-5943.
51. VAN DRIEL WJ, RESSING ME, KENTER GG et al.: Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a Phase 141 trial. Eur. J. Cancer (1999) 35:946-952.
52. STREET MD, DOAN T, HERD KA, TINDLE RW: Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus Type 16 E7 protein. Immunology (2002) 106:526-536.
53. EIBEN GL, VELDERS MP, SCHREIBER H et al.: Establishment of an HLA-A*0201 human papillomavirus Type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. (2002) 62:5792-5799. Improvement on E7-expressing transplantable tumour model.
54. FRAZER IH, LEIPPE DM, DUNN LA et al.: Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. (1995) 55:2635-2639.
55. ARBEIT JM, HOWLEY PM, HANAHAN D: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus Type 16 transgenic mice. Proc. Natl. Acad Sci. USA (1996) 93:2930-2935.
56. MELERO I, SINGHAL MC, MCGOWAN P et al.: Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus Type 16. J. Virol. (1997) 71:3998-4004.
57. FRAZER IH, FERNANDO GJ, FOWLER N et al.: Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. Eur. J. Immunol. (1998) 28:2791-2800.
58. FRAZER IH, DE KLUYVER R, LEGGATT GR et al.: Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. (2001) 167:6180-6187. Highlights importance of pro-inflammatory signalling for inducing immunity.
59. DOAN T, HERD KA, LAMBERT PF, FERNANDO GJ, STREET MD, TINDLE RW: Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. (2000) 60:2810-2815.
60. SCHILLER JT, LOWY DR: Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin. Biol. Ther. (2001) 1:571-581.
61. LENZ P, DAY PM, PANG YY et al.: Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. (2001) 166:5346-5355.
62. GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA (1998) 95:1800-1805.
63. NIELAND JD, DA SILVA DM, VELDERS MP et al.: Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J. Cell Biochem. (1999) 73:145-152.
64. WILCOX RA, FLIES DB, ZHU G et al.: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. (2002) 109:651-659.
65. ZWAVELING S, FERREIRA MOTA SC, NOUTA J et al.: Established human papillomavirus Type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. (2002) 169:350-358. Emphasises benefit of enhancing APC function for immunotherapeutic effect.
66. SHIRAI M, PENDLETON CD, AHLERS J, TAKESHITA T, NEWMAN M, BERZOFSKYJA: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. (1994) 152:549-556.
67. CHENG WF, HUNG CF, CHAI CY et al.: Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. (2001) 108:669-678.
68. JI H, WANG TL, CHEN CH et al.: Targeting human papillomavirus Type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus Type 16 E7-expressing tumors. Hum. Gene Ther. (1999) 10:2727-2740.
69. HUNG CF, HE L, JUANG J, LIN TJ, LING M, WU TC: Improving DNA vaccine potency by linking Marek's disease virus Type 1 VP22 to an antigen. J. Virol. (2002) 76:2676-2682.
70. ELLIS RJ: The molecular chaperone concept. Semin. Cell Biol. (1990) 1:1-9.
71. MIZZEN L: Immune responses to stress proteins: applications to infectious disease and cancer. Biotherapy (1998) 10:173-189.
72. CHEN CH, WANG TL, HUNG CF et al.: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. (2000) 60:1035-1042.
73. LIU DW, TSAO YP, KUNG JT et al.: Recombinant adeno-associated virus expressing human papillomavirus Type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. (2000) 74:2888-2894.
74. HSU KF, HUNG CF, CHENG WF et al.: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. (2001) 8:376-383.
75. CHENG WF, HUNG CF, CHAI CY et al.: Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J. Immunol. (2001) 166:6218-6226. First demonstration of RNA vaccine technology combined with Hsp fusion construct.
76. HUNT KK, VORBURGER SA: Tech. Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science (2002) 297:415-416.
77. ANTHONY LS, WU H, SWEET H, TURNNIR C, BOUX LJ, MIZZEN LA: Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nudeoprotein fusion molecule. Vaccine (1999) 17:373-383.
78. CHU NR, WU HB, WU T, BOUX LJ, SIEGEL MI, MIZZEN LA: Immunotherapy of a human papillomavirus (HPV) Type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. (2000) 121:216-225. First demonstration of BCG Hsp65/ HPV16 E7 fusion protein having ability to induce cellular immunity and tumour regression.
79. CHO BK, PALLISER D, GUILLEN E et al.: A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity (2000) 12:263-272.
80. SUZUE K, ZHOU X, EISEN HN, YOUNG RA: Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA (1997) 94:13146-13151.
81. VABULAS RM, AHMAD-NEJAD P, DA COSTA C et al.: Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. (2001) 276:31332-31339.
82. BULUT Y, FAURE E, THOMAS L et al.: Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J. Immunol. (2002) 168:1435-1440.
83. HABICH C, BAUMGART K, KOLB H, BURKART V: The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J. Immunol. (2002) 168:569-576.
84. WALLIN RP, LUNDQVIST A, MORE SH, VON BONIN A, KIESSLING R, LJUNGGREN HG: Heatshock proteins as activators of the innate immune system. Trends Immunol. (2002) 23:130-135.
85. BAUSINGER H, LIPSKER D, HANAU D: Heat-shock proteins as activators of the innate immune system. Trends Immunol. (2002) 23:342-343.
86. GASTON JS: Heat shock proteins and innate immunity. Clin. Exp. Immunol. (2002) 127:1-3.
87. ASEA A, KRAEFT SK, KURT-JONES EA et al.: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. (2000) 6:435-442.
88. LEWTHWAITE JC, COATES AR, TORMAY P et al.: Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain. Infect. Immun. (2001) 69:7349-7355.
89. BEUTLER B: Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. (2000) 12:20-26.
90. JAGER E, JAGER D, KNUTH A: Clinical cancer vaccine trials. Curr. Opin. Immunol. (2002) 14:178-182.
91. YEE C, RIDDELL SR, GREENBERG PD: In vivo tracking of tumor-specific T cells. Curr. Opin. Immunol. (2001) 13:141-146.
92. EVANS TG, BONNEZ W, ROSE RC et al.: A Phase I study of a recombinant viruslike particle vaccine against human papillomavirus Type 11 in healthy adult volunteers. J. Inject. Dis. (2001) 183:1485-1493.
93. EMENY RT, WHEELER CM, JANSEN KU et al.: Priming of human papillomavirus Type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. (2002) 76:7832-7842.
94. KAUFMANN AM, STERN PL, RANKIN EM et al.: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. (2002) 8:3676-3685.
95. MURAKAMI M, GURSIC KJ, MARINCOLA FM, ACKLAND J, STELLER MA: Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. (1999) 59:1184-1187.
96. SANTIN AD, HERMONAT PL, RAVAGGI A et al.: Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus Type 16- and 18-positive cervical cancer. J. Virol. (1999) 73:5402-5410.
97. EVANS M, BORYSIEWICZ LK, EVANS AS et al.: Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol (2001) 167:5420-5428.
98. SANTIN AD, BELLONE S, GOKDEN M, CANNON MJ, PARHAM GP: Vaccination with HPV- 18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. (2002) 346:1752-1753.
99. VAN DER BURG SH, KWAPPENBERG KM, O'NEILL T et al.: Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine (2001) 19:3652-3660.
100. STANLEY MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res. (2002) 89:241-248.
101. ZHANG LF, ZHOU J, CHEN S et al.: HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 18:1051-1058.
102. MUDERSPACH L, WILCZYNSKI S, ROMAN L et al.: A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar inrraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. (2000) 6:3406-3416.
103. KLENCKE B, MATIJEVIC M, URBAN RG et al.: Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. (2002) 8:1028-1037.
104. GOLDSTONE SE, PALEFSKY JM, WINNETT MT, NEEFE JR: Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum. (2002) 45:502-507.
105. PALEFSKY JM, GOLDSTONE SE, BOUX LJ, NEEFE JR: Pathological response to treatment with HspE7 in anal dysplasia of multiple HPV types. Cancer Vaccines 2000. New York, USA (2000).
106. KONYA J, DILLNER J: Immunity to oncogenic human papillomaviruses. Adv. Cancer Res. (2001) 82:205-238.
107. VAN DER BURG SH, RESSING ME, KWAPPENBERG KM et al.: Natural T-helper immunity against human papillomavirus Type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer. (2001) 91:612-618.